HilleVax Inc.

HLVX

Offer Price Offer Size 3-Year Outlook Volatility 1st Day Turnover
$17.00 11,770,000 Positive High 19.86%

Offering Team

Deal Managers

  • J P Morgan Chase
  • SVB Leerink
  • Stifel

Lawyers

  • Davis Polk & Wardwell LLP

Auditors

  • Ernst & Young LLP

Pre-IPO Investors

Investors

  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins

Pre-IPO Holdings(%)

  • 30
  • 20
  • 05
  • 18

Deal Highlights

We are founded on the legacies of leading vaccine developers who inspire us to build a company to benefit human health on a global scale. Our late co-founder, Dr. Tadataka “Tachi” Yamada, championed vaccines as a powerful means to address health inequities and equalize opportunity for people around the world. As the former Chief Medical and Scientific Officer at Takeda Pharmaceutical Company Limited (Takeda Pharmaceuticals), Tachi helped establish Takeda Pharmaceuticals More

Deal Tracker

Investors

Filing

28 Apr, 2022

Offer

29 Apr, 2022

Look Ahead

Lock Up Expiry

29 Oct, 2022

Earning

Nov 1, 2018

IPO Terms

Offer Price $17.00
Offer Size 11M

Market Sentiments

Stock Price